中信证券股份有限公司 关于恩威医药股份有限公司 使用部分闲置募集资金暂时补充流动资金的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）担任恩威 医药股份有限公司（以下简称"恩威医药"、"上市公司"或"公司"）首次公 开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则（2023 年修订）》《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关 规定，对恩威医药使用部分闲置募集资金暂时补充流动资金事项发表核查意见如 下： 一、本次募集资金的基本情况 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1786 号）同意注册，并经深圳证券交易所同 意，公司首次向社会公开发行人民币普通股（A 股）股票 17,540,000 股，每股面 值 1.00 元，发行价格为人民币 29.80 元/股。本次募集资金总额为人民币 522,692,000.00 元，扣除发行费用（不 ...

证券代码：301331 证券简称：恩威医药 4、胡先生你好！请问洁尔阴洗液 22 年的市占率是多少，是 否还有提升的空间？洁尔阴洗液在国内家喻户晓，是否考虑开拓 国外市场？谢谢 恩威医药股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | 路演活动 □ 新闻发布会 □ | | | 现场参观 □ | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 线上参与公司2022年度暨2023年一季度业绩网上说明会的投资 | | 人员姓名 | 者 | | 时间 | 2023 年 5 月 8 日 (周一) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、公司董事长兼首席执行官 薛永江 | | 员姓名 | 2、独立董事 冯建 | | | 3、财务负责人兼董事会秘书 胡大伟 | | | 4、保荐代表人 石 ...

Dividend Distribution - The company plans to distribute a cash dividend of 16.00 CNY per 10 shares (including tax) based on a total share capital of 70,138,359 shares[6]. - The total distributable profit for the year is 233,678,177.49 yuan, with cash dividends accounting for 100% of the profit distribution[160]. - The company aims for a cash dividend ratio of at least 80% for mature stages without major capital expenditures, and at least 40% with such expenditures[148]. - The company has a cash dividend policy that complies with its articles of association and shareholder resolutions, with clear standards and procedures[159]. - The company did not make any adjustments or changes to its cash dividend policy during the reporting period[159]. Financial Performance - The company's operating revenue for 2022 was approximately ¥691.57 million, representing a 1.75% increase compared to ¥679.70 million in 2021[19]. - The net profit attributable to shareholders decreased by 33.35% to approximately ¥67.80 million in 2022 from ¥101.73 million in 2021[19]. - The net profit after deducting non-recurring gains and losses was approximately ¥57.21 million, down 32.34% from ¥84.55 million in 2021[19]. - The total assets at the end of 2022 increased by 61.79% to approximately ¥1.41 billion from ¥869.09 million at the end of 2021[19]. - The net assets attributable to shareholders rose by 79.53% to approximately ¥1.15 billion at the end of 2022, compared to ¥642.25 million at the end of 2021[19]. - The company reported a basic earnings per share of ¥1.1898, down 38.49% from ¥1.9342 in 2021[19]. - The weighted average return on equity decreased to 8.62% in 2022 from 16.77% in 2021, a decline of 8.15 percentage points[19]. Market and Industry Outlook - The pharmaceutical industry in China is expected to continue growing rapidly, driven by factors such as economic growth, aging population, and increased health awareness[30]. - The retail terminal's market share for drug sales is anticipated to increase further due to ongoing healthcare reforms and the trend of prescription outflow[30]. - The Chinese government has issued multiple supportive policies for the pharmaceutical industry, creating a favorable environment for the company's sustained growth[33]. - The company anticipates that the pharmaceutical industry will undergo significant restructuring due to intensified regulatory policies and market competition, leading to a focus on compliance and high-quality development[89]. - The company expects that the ongoing implementation of consistency evaluation policies will significantly impact the competitive landscape and growth of the pharmaceutical industry, particularly affecting generic drug manufacturers[89]. Research and Development - The company is committed to innovation as a core task for high-quality development in the pharmaceutical industry, aligning with national strategic goals[34]. - Research and development expenses rose by 73.81% to ¥7,516,973.88, primarily due to increased investment in new product development[63]. - R&D investment increased significantly to ¥7,516,973.88 in 2022, representing 1.09% of operating revenue, up from 0.64% in 2021[66]. - The number of R&D personnel decreased by 5.13% from 39 in 2021 to 37 in 2022, with the proportion of R&D personnel to total employees at 2.30%[65]. - The company is advancing the development of generic drugs, with plans to initiate registration for a specific drug by Q4 2023[95]. Product and Market Strategy - The company focuses on the research, production, and sales of traditional Chinese medicine and chemical drugs, particularly in gynecology, pediatrics, and respiratory medicine[37]. - The core product, "Jieryin Wash," along with 16 other exclusive varieties, accounts for over 50% of the company's main business revenue[37]. - The company aims to enhance its leadership position in the gynecology product sector through self-research, joint research, and product acquisitions[37]. - The company is actively expanding its product range to include pediatric and respiratory medications, creating a diversified product portfolio[37]. - The company plans to expand its product line with new drugs targeting various medical conditions, enhancing market share[64]. Sales and Distribution - The sales model includes a combination of distribution through dealers and direct sales to consumers via e-commerce platforms, with a rapid increase in e-commerce sales[42]. - The online sales channel experienced a remarkable growth of 939.62%, reaching approximately ¥2.85 million in 2022, compared to ¥274,010.88 in 2021[54]. - The company has established long-term partnerships with over 1,700 domestic medium and large commercial companies, enhancing its nationwide distribution network[48]. - The company’s marketing network covers all 31 provinces and regions in China, utilizing a modern multi-channel approach[47]. - The company aims to achieve 700 million market exposures through social media and online marketing strategies in 2023[94]. Corporate Governance - The company strictly adheres to corporate governance regulations, ensuring transparency and compliance with laws such as the Company Law and Securities Law[104]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[107]. - The company maintains complete independence from its actual controllers in terms of business operations, personnel, assets, and finances[111]. - The company has established a robust internal management and control system to enhance operational independence and governance[112]. - The audit committee regularly communicates with auditors to monitor financial management and internal controls[107]. Environmental Compliance - Enwei Pharmaceutical's wastewater treatment system has a capacity of 300 tons per day, utilizing anaerobic tanks and advanced treatment processes[173]. - The company complied with multiple environmental protection laws and standards, including the "Environmental Protection Law" and "Water Pollution Prevention Law" during the reporting period[171]. - Enwei Pharmaceutical's wastewater discharge for COD was 173.2 mg/L, well below the standard limit of 500 mg/L, indicating no exceedance[172]. - The company has invested over 1.2 million yuan in environmental governance and protection as of the end of the reporting period[175]. - The company actively engages with investors through various channels, ensuring transparent communication and protection of shareholder rights[179]. Employee Management - The total number of employees at the end of the reporting period is 1,610, with 838 from the parent company and 772 from major subsidiaries[140]. - The company has established a competitive compensation and benefits system to enhance employee recognition and retention[141]. - The company plans to conduct over 50 employee training sessions in 2023, introducing a more advanced training management system[143]. - The company provides various employee benefits, including public holidays, traditional holiday benefits, and allowances for business trips[142]. - The company will consider reallocating employees who do not pass training assessments after multiple attempts[143]. Future Commitments and Responsibilities - The company reported a commitment to fulfill all public commitments made during its initial public offering and is open to social supervision[194]. - The company will take measures to compensate for any losses incurred due to unfulfilled commitments, including using cash dividends for compensation[194]. - The company has outlined specific actions to be taken in case of failure to meet commitments, including timely public disclosure of reasons and proposing alternative commitments to protect investor interests[194]. - The company will ensure compliance with relevant laws and regulations in all its operations[196]. - The company emphasizes the importance of transparency and accountability in its operations and commitments to shareholders[195].

[Key Financial Data](index=2&type=section&id=Item%201.%20Key%20Financial%20Data) [Core Financial Indicators](index=2&type=section&id=Item%20%281%29.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2023, the company achieved robust performance with **$201 million** in operating revenue and **$27.67 million** in net profit attributable to shareholders, alongside positive operating cash flow and stable financial health | Indicator | Current Period | Prior Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue ($) | 200,800,387.47 | 157,604,605.75 | 27.41% | | Net Profit Attributable to Shareholders ($) | 27,669,629.76 | 20,258,223.51 | 36.58% | | Net Cash Flow from Operating Activities ($) | 505,655.16 | -4,394,061.58 | 111.51% | | Basic Earnings Per Share ($/share) | 0.3945 | 0.3851 | 2.44% | | **Balance Sheet Indicators** | **End of Current Period** | **End of Prior Year** | **Change from Year-End** | | Total Assets ($) | 1,431,675,016.45 | 1,406,080,553.60 | 1.82% | | Total Equity Attributable to Shareholders ($) | 1,180,672,946.34 | 1,153,003,316.58 | 2.40% | [Non-Recurring Gains and Losses Analysis](index=2&type=section&id=Item%20%282%29.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for the period amounted to **$1.876 million**, positively impacting current net profit, primarily comprising **$1.174 million** in government grants and **$1.066 million** in investment income from transactional financial assets | Item | Amount for Current Period ($) | | :--- | :--- | | Gains and Losses from Disposal of Non-Current Assets | -41,203.90 | | Government Grants | 1,174,435.23 | | Gains and Losses Related to Transactional Financial Assets | 1,065,912.13 | | Other Non-Operating Income and Expenses | 10,073.57 | | Less: Income Tax Impact | 332,789.22 | | **Total** | **1,876,427.81** | [Reasons for Changes in Key Financial Indicators](index=2&type=section&id=Item%20%283%29.%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The growth in key profit indicators for the period is primarily attributed to increased operating revenue, while the significant improvement in operating cash flow (up 111.51%) resulted from increased sales collections, indicating enhanced core business cash generation - The increase in net profit attributable to shareholders (up **36.58%** year-over-year) and non-recurring net profit (up **30.49%** year-over-year) was primarily due to increased operating revenue[8](index=8&type=chunk) - Net cash flow from operating activities increased by **111.51%** year-over-year, turning positive, primarily due to increased sales collections[9](index=9&type=chunk) [Shareholder Information](index=3&type=section&id=Item%202.%20Shareholder%20Information) [Shareholder Ownership Structure](index=3&type=section&id=Item%20%281%29.%20Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the end of the reporting period, the company had **10,849** common shareholders, with a concentrated equity structure where the top four shareholders are related parties collectively holding over **65%** of shares, and the actual controllers Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong indirectly control **67.23%** of the company's equity through concerted action agreements - The total number of common shareholders at the end of the reporting period was **10,849**[10](index=10&type=chunk) - The company's actual controllers, Xue Yongxin, Xue Yongjiang, Xue Gang, and Xue Weihong, indirectly control **67.23%** of the company's equity through Enwei Group, Chengdu Jiewei, Chengdu Ruijinheng, Chengdu Zehong, and Changdu Jieweite, forming a concerted action group[10](index=10&type=chunk) - The largest shareholder, Chengdu Enwei Investment (Group) Co., Ltd., holds **28.64%** of the company's shares, with a portion (**4.5 million** shares) pledged[10](index=10&type=chunk) [Other Significant Matters](index=4&type=section&id=Item%203.%20Other%20Significant%20Matters) [Other Significant Matters](index=4&type=section&id=Item%203.%20Other%20Significant%20Matters) During the reporting period, the company had no other significant matters requiring disclosure - The company had no other applicable or significant matters to explain during this reporting period[12](index=12&type=chunk) [Quarterly Financial Statements](index=4&type=section&id=Item%204.%20Quarterly%20Financial%20Statements) [Consolidated Balance Sheet](index=4&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of March 31, 2023, the company's total assets were **$1.432 billion**, up 1.82% from the beginning of the year with a stable asset structure, while total liabilities slightly decreased to **$251 million**, and shareholders' equity increased by 2.40% to **$1.181 billion**, primarily due to accumulated current period profits | Item | End of Period Balance ($) | Beginning of Year Balance ($) | | :--- | :--- | :--- | | **Total Assets** | **1,431,675,016.45** | **1,406,080,553.60** | | Total Current Assets | 987,194,143.53 | 957,287,374.17 | | Total Non-Current Assets | 444,480,872.92 | 448,793,179.43 | | **Total Liabilities** | **251,002,070.11** | **253,077,237.02** | | **Total Shareholders' Equity** | **1,180,672,946.34** | **1,153,003,316.58** | [Consolidated Income Statement](index=6&type=section&id=2.%20Consolidated%20Income%20Statement) In Q1 2023, the company achieved total operating revenue of **$201 million**, a 27.41% year-over-year increase, with operating costs up 24.8%, selling expenses up 36.3%, and R&D expenses significantly increasing by 124.8%, ultimately resulting in a net profit attributable to parent company shareholders of **$27.67 million**, up 36.58% | Item | Amount for Current Period ($) | Amount for Prior Period ($) | | :--- | :--- | :--- | | **I. Total Operating Revenue** | **200,800,387.47** | **157,604,605.75** | | **II. Total Operating Costs** | **168,140,196.62** | **134,049,118.32** | | Selling Expenses | 59,019,548.45 | 43,296,237.94 | | Research and Development Expenses | 2,127,675.84 | 946,766.85 | | **III. Operating Profit** | **34,137,438.81** | **23,128,821.52** | | **V. Net Profit** | **27,669,629.76** | **20,258,223.51** | [Consolidated Cash Flow Statement](index=7&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement) In Q1 2023, the company's cash flow significantly improved, with net cash flow from operating activities turning positive at **$0.506 million** from -$4.394 million in the prior year, and net cash flow from investing activities at **$22.06 million** primarily due to cash received from investment-related activities, increasing the period-end cash and cash equivalents balance to **$364.12 million** | Item | Amount for Current Period ($) | Amount for Prior Period ($) | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | **505,655.16** | **-4,394,061.58** | | **Net Cash Flow from Investing Activities** | **22,062,212.40** | **-11,212,372.79** | | **Net Cash Flow from Financing Activities** | **0.00** | **-352,000.00** | | **Net Increase in Cash and Cash Equivalents** | **22,541,970.22** | **-15,966,410.88** | | **End of Period Cash and Cash Equivalents Balance** | **364,120,291.46** | **48,283,675.61** | [Audit Information](index=9&type=section&id=Item%20%282%29.%20Audit%20Report) The company's Q1 2023 financial report was unaudited - The company's first-quarter report was unaudited[21](index=21&type=chunk)

证券代码：301331 证券简称：恩威医药 公告编号：2023-007 恩威医药股份有限公司 关于举行 2022 年度暨 2023 年一季度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 欢迎广大投资者积极参与本次网上说明会。 特此公告。 恩威医药股份有限公司董事会 2023 年 4 月 22 日 恩威医药股份有限公司（以下简称"公司"）定于 2023 年 5 月 8 日（星期一）下午 15：00-17：00 在全景网举办 2022 年度暨 2023 年一季度业绩网上说明会，本次年度业 绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼首席执行官薛永江、财务负责人兼董事会 秘书胡大伟、独立董事冯建、保荐代表人石坡。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度暨 2023 年一季度业绩 网上说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 8 日（星期一 ...